News

Featured News

  • 2024 |
  • 2023 |
  • 2022 |
  • 2021 |
  • 2020 |
  • 2019 |
  • 2018 |
  • 2017 |
  • View All
  • Press Release | May 28, 2024

    Affini-T Therapeutics Announces First Patient Dosed in KRAS G12V Phase 1 Program and Presentation of Trial-in-Progress Poster at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting

    Read More

    Video | May 6, 2024

    BIOSECURE Act Discussion featuring Cartier Esham, Ph.D. of BIO

    Read More

    Press Release | April 2, 2024

    Freenome Announces Topline Results for PREEMPT CRC® to Validate the First Version of its Blood-Based Test for the Early Detection of Colorectal Cancer

    Read More

    News | March 25, 2024

    Q32 Bio Announces Closing of Merger with Homology Medicines and Concurrent Private Placement of $42 Million

    Read More

    News | February 21, 2024

    Q32 Bio Announces Publication of Preclinical Data in Molecular Therapy Demonstrating the Therapeutic Potential of Tissue-Targeted Complement Inhibitor ADX-097 for Complement-Mediated Diseases

    Read More

    Press Release | February 15, 2024

    Freenome Raises $254 Million in New Funding to Accelerate its Platform for Early Cancer Detection

    Read More

    Press Release | February 8, 2024

    Metagenomi Announces Pricing of Initial Public Offering

    Read More

    Press Release | February 4, 2024

    Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis

    Read More

    Press Release | December 14, 2023

    First In Vivo CAR-M Lead Candidate Nominated Under Carisma-Moderna Collaboration

    Read More

    Press Release | December 7, 2023

    Vittoria Biotherapeutics Announces FDA Clearance of IND Application for VIPER-101 to Treat T-Cell Lymphoma

    Read More

    Press Release | December 5, 2023

    Dragonfly Therapeutics Initiates Phase 1/1b Study of its IL-2 Immunotherapy in Patients with Advanced Solid Tumors

    Read More

    Press Release | November 28, 2023

    Carisma Therapeutics Announces FDA Clearance of IND Application for CT-0525, a Novel HER2-Targeting CAR-Monocyte

    Read More

    Press Release | November 20, 2023

    Cantai Therapeutics is Co-Founded by Agent Capital and 82VS to Advance Next-Generation Bispecific Antibodies for Autoimmune Diseases

    Read More

    News | October 25, 2023

    A new era in medicine: unraveling the evolution and future of gene therapy

    Read More

    News | October 23, 2023

    Skyhawk Therapeutics Receives HREC Approval for a Phase 1 Study of its SKY-0515 RNA-Targeting Small Molecule for Huntington’s Disease

    Read More

    News | October 19, 2023

    Flare Therapeutics Announces First Patients Dosed in First-in-Human Phase 1 Clinical Study of FX-909 in Advanced Solid Malignancies, Including Urothelial Cancer

    Read More

    News | October 16, 2023

    ImCheck to Present New Positive Data on ICT01 Monotherapy in Hematological Cancers at ESMO 2023

    Read More

    Press Release | October 5, 2023

    Kyowa Kirin to Acquire Orchard Therapeutics

    Read More

    Press Release | September 26, 2023

    Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from Phase 2a INTEGRIS-PSC Clinical Trial of Bexotegrast in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis

    Read More

    Press Release | September 21, 2023

    Entrada Therapeutics Announces First Participant Dosed in its Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy

    Read More

    News | September 20, 2023

    ImCheck has been short-listed among the top 10 “Biotech et Medtech” companies for the 2023 edition of Les Trophées des Futures Licornes, which rewards the growth potential of innovative French companies.

    Read More

    Press Release | September 5, 2023

    Zenas BioPharma Announces Strategic License and Collaboration Agreement with Bristol Myers Squibb

    Read More

    Press Release | September 5, 2023

    Star Therapeutics raises $90 million financing to accelerate its pipeline of novel antibody therapies and growth of its portfolio companies

    Read More

    News | August 25, 2023

    Investing long-term in the cell & gene therapies of the future (Podcast with Geeta Vemuri and David McCall)

    Read More

    Press Release | August 23, 2023

    Pyxis Oncology Successfully Completes Acquisition of Apexigen

    Read More

    News | August 17, 2023

    Patent Awarded for Primary Template-Directed Amplification, Further Strengthening BioSkryb Genomics’ Core Technologies

    Read More

    Press Release | August 15, 2023

    Precision BioSciences Completes Strategic Transaction with Imugene for Azer-Cel in Cancer

    Read More

    Press Release | August 3, 2023

    Orchard Therapeutics Completes Submission of Biologics License Application for OTL-200 in MLD to U.S. FDA

    Read More

    Press Release | August 1, 2023

    Zenas BioPharma Announces Publication of Phase 2 Study of Obexelimab, an Investigational Treatment for IgG4-Related Disease (IgG4-RD), in The Lancet Rheumatology

    Read More

    Press Release | August 1, 2023

    Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy

    Read More

    Press Release | July 20, 2023

    Palvella Therapeutics Announces Planned Pivotal Phase 3 Study Design of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations and Topline Results from Phase 2b CODY Study in Gorlin Syndrome

    Read More

    Press Release | June 28, 2023

    Carisma Therapeutics Announces First Patient Dosed in Phase 1 Study of CT-0508 in Combination with KEYTRUDA® (pembrolizumab) in Patients with HER2 Overexpressing Solid Tumors

    Read More

    News | June 21, 2023

    Interius BioTherapeutics Highlights Strong Preclinical Data Supporting In Vivo Chimeric Antigen Receptor (CAR) Vector Evaluation in Clinic

    Read More

    Press Release | June 20, 2023

    Lilly to Acquire DICE Therapeutics to Advance Innovation in Immunology

    Read More

    Press Release | June 15, 2023

    Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS

    Read More

    News | June 15, 2023

    ImCheck selected as laureate of the new French Tech 2030 program

    Read More

    Press Release | June 15, 2023

    Walgreens and Freenome Establish Partnership to Increase Diversity in Research for the Early Detection of Cancer

    Read More

    Press Release | June 5, 2023

    Dragonfly Therapeutics Announces the Presentation of Phase 1 DF1001 TriNKET® Dose Escalation Results

    Read More

    Press Release | June 2, 2023

    Affini-T Therapeutics Appoints Industry Veteran Thaminda Ramanayake, M.S., MBA, as Chief Business Officer

    Read More

    Press Release | June 1, 2023

    Dr. Robin Edwards and Dr. David Ferry join Dragonfly’s Clinical Leadership Team to help Manage its Growing Clinical Pipeline

    Read More

    Press Release | May 30, 2023

    Pyxis Oncology Advances PYX-106 and PYX-201 Clinical Programs

    Read More

    Press Release | May 24, 2023

    Pyxis Oncology to Acquire Apexigen

    Read More

    Press Release | May 22, 2023

    Freenome Acquires Global Immunodiagnostics Developer Oncimmune Ltd

    Read More

    Press Release | May 22, 2023

    Freenome Acquires Global Immunodiagnostics Developer Oncimmune Ltd

    Read More

    Press Release | May 19, 2023

    Metagenomi to Present New Data for Its Novel Gene-Editing Systems at the 26th American Society of Gene + Cell Therapy (ASGCT) Annual Meeting

    Read More

    Press Release | May 19, 2023

    Orchard Therapeutics Announces Positive Clinical and Preclinical Data in Programs Targeting Neurometabolic and CNS Disorders at ASGCT

    Read More

    Press Release | May 19, 2023

    Orchard Therapeutics Announces Positive Clinical and Preclinical Data in Programs Targeting Neurometabolic and CNS Disorders at ASGCT

    Read More

    News | May 16, 2023

    Cyrus Bio Scientist Erik Procko and the company’s lead ACE2-Fc Fusion protein COVID-19 therapeutic are featured in Science news article

    Read More

    Press Release | April 27, 2023

    Foresight Diagnostics announces $58.75 Million Series B financing led by Foresite Capital to commercialize ultrasensitive liquid biopsy MRD testing platform

    Read More

    Press Release | April 26, 2023

    Orbital Therapeutics Secures $270 Million in Series A Financing to Unleash Full Potential of RNA Medicines

    Read More

    Press Release | April 18, 2023

    ImCheck Achieves the Primary Objectives of Phase I of the EVICTION-2 Trial of ICT01 in Combination with Low Dose IL-2, Data Presented at AACR 2023

    Read More

    News | April 16, 2023

    Dragonfly Therapeutics Announces the Publication of Preclinical Data

    Read More

    Press Release | April 13, 2023

    Caris Life Sciences and Flare Therapeutics Announce Strategic Preferred Portfolio Partnership to Advance Flare’s Precision Oncology Pipeline

    Read More

    News | March 26, 2023

    Investing long-term in the cell & gene therapies of the future

    Read More

    News | March 22, 2023

    Flare Therapeutics Announces Oversubscribed $123 Million Series B Financing

    Read More

    Press Release | March 16, 2023

    Pyxis Oncology Announces Dosing of First Subject in Phase 1 Trial of PYX-201, a Novel ADC for Solid Tumors

    Read More

    News | March 15, 2023

    Passage of FDA Modernization Act 2.0 Opens Opportunities for New Alternative Methods in Drug Development

    Read More

    Press Release | March 13, 2023

    Pliant Therapeutics Announces Positive DSMB Safety Review and Initiation of Enrollment of Phase 2a Trial of Bexotegrast (PLN-74809) at 320 mg Dose in Primary Sclerosing Cholangitis

    Read More

    Press Release | March 9, 2023

    Palvella Therapeutics Announces Positive Topline Results from Phase 2 Study of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations, a Serious, Rare Genetic Skin Disease with No FDA-approved Therapies

    Read More

    News | March 7, 2023

    Carisma Therapeutics Closes Merger with Sesen Bio

    Read More

    Press Release | March 6, 2023

    Orchard Therapeutics Announces Strategic Financing Totalling up to $188 Million

    Read More

    Press Release | March 3, 2023

    Affini-T Therapeutics to Present Data from Lead Oncogenic Driver Candidate at AACR Special Conference: Targeting RAS

    Read More

    Press Release | March 2, 2023

    Metagenomi Recognized as One of World’s Most Innovative Companies by Fast Company

    Read More

    Press Release | March 1, 2023

    DICE Therapeutics Announces Late-Breaking Presentation at the 2023 American Academy of Dermatology (AAD) Annual Meeting

    Read More

    News | February 27, 2023

    Pathway to Cures Appoints Investment Committee

    Read More

    Press Release | February 2, 2023

    Pliant Therapeutics Announces FDA Clearance of Investigational New Drug Application for PLN-101095, A Novel Integrin Inhibitor for the Treatment of Solid Tumors

    Read More

    Press Release | February 1, 2023

    Dr. Joseph E. Eid, Who Led Merck’s Pioneering Clinical Development of KEYTRUDA®, joins Dragonfly Therapeutics as President of R&D

    Read More

    Press Release | January 31, 2023

    Carisma Therapeutics Appoints Leading Solid Tumor Immunotherapy Expert Padmanee Sharma, MD, PhD to Scientific Advisory Board

    Read More

    Press Release | January 27, 2023

    Pliant Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

    Read More

    Press Release | January 22, 2023

    Pliant Therapeutics Announces Positive Data from the INTEGRIS-IPF Phase 2a Trial Demonstrating Bexotegrast 320 mg was Well Tolerated and Achieved Statistically Significant FVC Increase in Patients with Idiopathic Pulmonary Fibrosis

    Read More

    Press Release | January 18, 2023

    Freenome Partners with Geisinger for the Sanderson Study

    Read More

    Education | January 12, 2023

    Agent Capital’s Associate, Jonathan Ark’s PhD Work Published in Cell

    Read More

    Press Release | January 11, 2023

    Zenas BioPharma Announces First Patient Dosed in Phase 3 Clinical Study of Obexelimab for the Treatment of Immunoglobulin G4-Related Disease (IgG4-RD)

    Read More

    Press Release | January 9, 2023

    Orchard Therapeutics Highlights Recent Progress Across HSC Gene Therapy Portfolio and Outlines Key 2023 Milestones

    Read More

    Press Release | January 6, 2023

    Dragonfly Therapeutics Announces Sixth Dragonfly TriNKET Opt-in by Bristol Myers Squibb

    Read More

    Press Release | January 6, 2023

    Precision BioSciences Receives Favorable Type C Feedback from the FDA on the Company’s Chemistry, Manufacturing, and Controls (CMC) Strategies for Late-Stage Development of Azercabtagene Zapreleucel, its Lead Allogeneic CAR T Clinical Candidate

    Read More

    Press Release | January 5, 2023

    Palvella Therapeutics Announces Series D Financing of Up to $37.7 Million to Accelerate Late-Stage Development and Support Commercialization of Novel Therapies for Serious, Rare Genetic Skin Diseases

    Read More

    Press Release | January 5, 2023

    Orchard Therapeutics Announces U.S. FDA Clearance of IND Application for OTL-203 in MPS-IH

    Read More

    Press Release | January 5, 2023

    Metagenomi Closes Oversubscribed Series B Financing Totaling $275M to Advance Lead Therapeutic Programs into Clinical Development and Grow Genetic Medicines Pipeline

    Read More

    News | January 4, 2023

    Top Life Sciences Startups to Watch in 2023

    Read More

    Press Release | January 4, 2023

    Immunitas Therapeutics Announces First Patient Dosed in Phase 1/2a Study of IMT-009

    Read More

    News | January 3, 2023

    Viewpoint: Expanding TRIPS waiver is bad for innovation

    Read More

    News | December 15, 2022

    Metagenomi Announces Publication of Data in Nature Communications Describing Novel, Ultra-Small Nucleases for Gene Editing

    Read More

    Press Release | December 15, 2022

    Pliant Therapeutics Receives Orphan Designation from the European Medicines Agency for Bexotegrast (PLN-74809) for the Treatment of Idiopathic Pulmonary Fibrosis

    Read More

    Press Release | December 12, 2022

    Orchard Therapeutics Announces Promising Early Neurocognitive Outcomes from Ongoing Proof-of-concept Study of OTL-201 in MPS-IIIA

    Read More

    Press Release | December 12, 2022

    Freenome Presents Research Highlighting The Promise of Identifying Drug-Response Biomarker for DLBCL Patients

    Read More

    Press Release | December 8, 2022

    Vertex and Entrada Therapeutics Establish Collaboration to Discover and Develop Endosomal Escape Vehicle (EEV) Therapeutics for Myotonic Dystrophy Type 1 (DM1)

    Read More

    Press Release | December 8, 2022

    Dragonfly Therapeutics Announces First Patient Dosed in Phase 1 Study of its EGFR-targeting TriNKET™

    Read More

    Press Release | November 24, 2022

    Proud to congratulate ImCheck’s scientific founder, Prof. Daniel Olive, on his election as President of the French Society of Immunology

    Read More

    Press Release | November 15, 2022

    ElevateBio and Affini-T Therapeutics Announce Partnership to Advance Affini-T’s T Cell Therapy Programs Targeting Core Oncogenic Drivers

    Read More

    News | November 14, 2022

    Ionis, Metagenomi pen Big Pharma-sized genetic target pact that could total almost $3B

    Read More

    Press Release | November 11, 2022

    ImCheck Presents Initial Patient Data from the EVICTION-2 Clinical Trial at SITC Annual Meeting

    Read More

    Press Release | November 7, 2022

    Affini-T Therapeutics to Present Preclinical Data from its Lead Programs Targeting KRAS G12V at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

    Read More

    Press Release | November 7, 2022

    Zenas BioPharma Secures $118 Million to Advance Its Broad Pipeline of Autoimmune Disease Therapeutics

    Read More

    Press Release | November 1, 2022

    Dragonfly Announces First Patient Dosed in Clinical Trial with Merck Evaluating Solid Tumor Target

    Read More

    Press Release | October 11, 2022

    DICE Therapeutics Announces Positive Topline Data from Phase 1 Clinical Trial of Lead Oral IL-17 Antagonist, DC-806, for Psoriasis

    Read More

    Press Release | October 3, 2022

    Metagenomi Announces Opening of Manufacturing Facility for its Next Generation CRISPR Gene-Editing Systems and Therapies

    Read More

    News | September 22, 2022

    Affini-T Therapeutics Named to the 2022 Endpoints 11

    Read More

    News | September 22, 2022

    Metagenomi Named an Endpoints 11 Winner

    Read More

    News | September 21, 2022

    Sesen Bio and Carisma Therapeutics Announce Merger Agreement

    Read More

    Press Release | September 10, 2022

    ImCheck Presents Positive Safety and Efficacy Data from the Completed Phase 1 Dose Escalation Cohort of ICT01 plus Pembrolizumab in the EVICTION Trial at ESMO Congress 2022

    Read More

    Press Release | September 1, 2022

    Pliant Therapeutics Announces Positive DSMB Safety Review of INTEGRIS-IPF Phase 2a Trial of PLN-74809 at 320 mg Dose in Idiopathic Pulmonary Fibrosis

    Read More

    Press Release | July 26, 2022

    Affini-T Therapeutics Appoints Pioneering T Cell Therapy and KRAS Developer Dirk Nagorsen, M.D., as Chief Medical Officer

    Read More

    Press Release | July 11, 2022

    Pliant Therapeutics Announces Positive Safety and Efficacy Data from Phase 2a INTEGRIS-IPF Clinical Trial of PLN-74809 in Patients with Idiopathic Pulmonary Fibrosis

    Read More

    Press Release | July 5, 2022

    Skyhawk Announces Collaboration Agreement with Sanofi for Oncology and Immunology Targets

    Read More

    Press Release | June 21, 2022

    Carbon Biosciences Launches with $38 Million Series A Financing to Advance Novel Gene Therapy Platform and Pipeline

    Read More

    Press Release | June 13, 2022

    ImCheck Closes Upsized EUR 96 Million (USD 103 Million) Financing to Advance Clinical Program of First-in-human Gamma-delta T Cell Activating Antibody and Accelerate Development of Disruptive Immunotherapeutic Pipeline

    Read More

    Press Release | May 15, 2022

    Zenas BioPharma Submits Investigational New Drug Application in China for ZB001 for the Treatment of Thyroid Eye Disease

    Read More

    Press Release | May 2, 2022

    Gilead follows Big Pharma peers to Dragonfly’s pond in $300M deal for natural killer cell engagers

    Read More

    Press Release | April 20, 2022

    Dragonfly Therapeutics Announces Multi-Target Expansion of its Research Collaboration with AbbVie to Develop Novel Therapeutic Candidates for Immune-Mediated Diseases

    Read More

    Press Release | April 8, 2022

    ImCheck Provides Updated ICT01 and Pembrolizumab Combination Data from the Phase I/IIa EVICTION Trial at AACR Annual Meeting 2022

    Read More

    Press Release | April 8, 2022

    Pyxis Oncology Announces Preclinical Data on Anti-Siglec-15 BSI-060T (PYX-106) Presented by Biosion, Inc. at the 2022 American Association for Cancer Research (AACR) Annual Meeting

    Read More

    News | March 22, 2022

    Affini-T Therapeutics Completes $175 Million Financing Co-Led by Vida Ventures and Leaps by Bayer to Advance Groundbreaking T Cell Therapies for Solid Tumor Patients with Oncogenic Driver Mutations

    Read More

    Press Release | March 1, 2022

    Dragonfly Therapeutics Announces Achievement of Phase 1 Clinical Development Milestone for IL-12 Investigational Immunotherapy Program with Bristol Myers Squibb

    Read More

    Press Release | February 28, 2022

    Freenome Launches the Vallania Study for the Early Detection of Multiple Cancers

    Read More

    News | February 28, 2022

    Aptinyx Completes Enrollment in Phase 2b Study of NYX-2925 in Fibromyalgia

    Read More

    Press Release | February 24, 2022

    Pliant Therapeutics Announces Positive DSMB Safety Review and Commencement of Enrollment of Phase 2a Trial of PLN-74809 at 320 mg Dose in Idiopathic Pulmonary Fibrosis

    Read More

    Press Release | February 3, 2022

    Orchard Therapeutics Announces Historic Agreement Making Libmeldy Available by NHS England for MLD Patients

    Read More

    News | January 28, 2022

    Cyrus Biotechnology CEO Lucas Nivon featured in Fierce Biotech Webinar

    Read More

    News | January 25, 2022

    Metagenomi Closes Oversubscribed $175M Series B Financing to Advance Therapeutic Pipeline and Expand Novel Gene Editing Platform

    Read More

    Press Release | January 19, 2022

    Orbus Therapeutics’ Phase 3 Eflornithine STELLAR Study Reaches Full Patient Enrollment

    Read More

    Press Release | January 6, 2022

    Zenas BioPharma Appoints Dr. John Orloff to Board of Directors

    Read More

    News | December 16, 2021

    Verge Genomics Secures $98 Million in New Financing

    Read More

    Press Release | December 9, 2021

    Interius BioTherapeutics Announces Granting of US Patent to Support in Vivo Cell-Specific Gene Delivery Platform

    Read More

    News | December 1, 2021

    Entrada Therapeutics: Advancing A New Class Of Medicines Called EEV

    Read More

    News | December 1, 2021

    Cyrus Biotechnology

    Read More

    News | December 1, 2021

    Zenas BioPharma

    Read More

    Press Release | November 23, 2021

    Dragonfly Announces Merck Opt-In on Second TriNKET

    Read More

    News | November 12, 2021

    ImCheck Provides Promising Updated Patient Response Data from the Phase I/IIa EVICTION Trial with ICT01 at SITC Meeting 2021

    Read More

    News | October 20, 2021

    imCheck Publishes Comprehensive Overview of the Developmenet Resumts of its First-in-class Cancer Immunotherapeutic Targeting BTN3A to Activate Cells in Science Translational Medicine

    Read More

    Press Release | October 18, 2021

    Dragonfly Therapeutics Announces Sixth Dragonfly Drug to be Licensed by Bristol Myers Squibb and Receipt of Milestone Payments Following First Patient Dosing of Two TriNKET™ Immunotherapies

    Read More

    Press Release | October 13, 2021

    Agent Capital Adds Dr. John Orloff as Venture Partner

    Read More

    Press Release | October 11, 2021

    Pyxis IPO leads way as four life science firms kick off 4Q, raising nearly $500M

    Read More

    Press Release | October 8, 2021

    Pyxis Oncology Raises $168M in Upsized IPO

    Read More

    Press Release | October 8, 2021

    Precision BioSciences Statement on Safety of its Allogeneic CAR T Cells

    Read More

    Press Release | October 4, 2021

    New Study Finds Freenome’s Multiomics Approach Successful in Detecting Pancreatic Cancer

    Read More

    Press Release | October 4, 2021

    Research Highlights Freenome’s Blood Test for Colorectal Cancer to Primary Care Physicians

    Read More

    Press Release | October 1, 2021

    ImCheck to Present Updated Patient Response Data from the EVICTION Trial and Additional ICT01 Results at the SITC Annual Meeting 2021

    Read More

    News | September 28, 2021

    Orbus Therapeutics Granted European Patent for Method of Use for Eflornithine

    Read More

    News | September 17, 2021

    Skyhawk Therapeutics Completes New Investment Round

    Read More

    News | September 17, 2021

    DICE Therapeutics Announces Pricing of Upsized Initial Public Offering

    Read More

    News | September 17, 2021

    ImCheck Presents Preliminary Patient Response Data from the Phase I/IIa EVICTION Trial with ICT01 at ESMO Congress 2021

    Read More

    News | September 14, 2021

    Bill Haney adds another $133M to Skyhawk’s coffers, as the RNA startup guns for the clinic

    Read More

    Press Release | September 14, 2021

    Skyhawk Therapeutics Completes New Investment Round

    Read More

    Press Release | September 8, 2021

    Immunitas Therapeutics Appoints Seng-Lai ‘Thomas’ Tan, Ph.D. as Chief Scientific Officer

    Read More

    Press Release | August 18, 2021

    Immunitas Therapeutics Completes $58 Million Series B Financing to Advance Pipeline into the Clinic and Expand Single Cell Analysis Drug Development Platform for Immuno-Oncology and Other Diseases

    Read More

    News | July 13, 2021

    ImCheck Publishes Seminal Paper in Cell Reports Elucidating How Butyrophilins Activate Vγ9Vδ2 T cell Function Against Tumor Cells

    Read More

    News | June 1, 2021

    Alloy Therapeutics and Pyxis Oncology Form Kyma Therapeutics to Develop Novel Immune-Modulating Antibodies for Cancer and Autoimmune Diseases

    Read More

    News | May 18, 2021

    Interius BioTherapeutics Raises $76M Series A Financing to Advance Breakthrough Cell and Gene Therapy Platform

    Read More

    Press Release | March 31, 2021

    Entrada Therapeutics Announces Closing of $116 Million Series B Financing

    Read More

    Press Release | March 30, 2021

    Pyxis Oncology Closes $152 Million Series B Financing to Further Advance Portfolio of Biologics

    Read More

    Press Release | March 18, 2021

    Pyxis Oncology Announces Worldwide Licensing Agreement with Pfizer to Develop and Commercialize Multiple Antibody-Drug Conjugates

    Read More

    News | March 18, 2021

    CAR-M era begins as Carisma doses first patient

    Read More

    News | January 8, 2021

    DiCE gets its ‘library’ card ready as it speeds development of DNA database-derived molecules with more investor cash

    Read More

    News | January 7, 2021

    CARISMA Therapeutics Completes Series B Funding to Advance Development of Novel CAR-Macrophage Immunotherapies

    Read More

    Press Release | December 21, 2020

    Orchard Therapeutics Receives EC Approval for Libmeldy™ for the Treatment of Early-Onset Metachromatic Leukodystrophy (MLD)

    Read More

    News | November 20, 2020

    Lilly, Precision Biosciences team up on Duchenne gene therapy in $135M deal

    Read More

    Press Release | November 5, 2020

    Orchard Therapeutics Announces New OTL-201 Clinical Data in Sanfilippo Syndrome Type A (MPS-IIIA) Accepted for Oral Presentation at 62nd American Society of Hematology Annual Meeting

    Read More

    News | November 3, 2020

    Orbus Therapeutics Publishes in Oncotarget Scientific Journal

    Read More

    Press Release | October 22, 2020

    Orbus Therapeutics Expands Series A Financing to $71 Million to Support Ongoing STELLAR Phase 3 Study in Rare Brain Cancer

    Read More

    Press Release | October 19, 2020

    Aptinyx Reports Positive, Statistically Significant, Top-line Data From Phase 2 Study of NYX-783 in Patients With Post-Traumatic Stress Disorder

    Read More

    Press Release | October 15, 2020

    Precision BioSciences Announces U.S. Patent Trial and Appeal Board Upholds Allogeneic CAR T Patents

    Read More

    Press Release | October 14, 2020

    ImCheck Announces Four ICT01 Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer 35th Anniversary Annual Meeting

    Read More

    Press Release | October 9, 2020

    Geeta Vemuri named Top 100 Powerful Women of 2020 by Entrepreneur

    Read More

    News | October 1, 2020

    Skyhawk Therapeutics Named Top 11 Biotech Startup 2020 by Endpoints News

    Read More

    Press Release | September 17, 2020

    Precision BioSciences and Servier Expand CAR T Oncology Development Collaboration with Four New Programs Targeting Hematological and Solid Tumors

    Read More

    Press Release | September 10, 2020

    ImCheck Achieves Initial Positive Independent Safety Review and Initiates Next Stage of Phase I/IIa EVICTION Trial for ICT01. Company Receives FDA Approval for US IND

    Read More

    News | August 26, 2020

    Freenome Closes $270 Million Series C Financing to Advance Novel Multiomics Blood Testing Platform for Early Cancer Detection

    Read More

    News | August 17, 2020

    BMS Licenses IL-12 from Dragonfly in $475 Million Upfront Deal

    Read More

    News | July 29, 2020

    Women in Bio: Geeta Vemuri Blazes a Trail in Venture Capital

    Read More

    Press Release | July 27, 2020

    CARISMA Therapeutics Announces FDA Clearance of IND Application for First-Ever Engineered Macrophage Immunotherapy

    Read More

    News | July 23, 2020

    Clearing the Hurdles to a Career in Venture Capital; An Interview with Geeta Vemuri

    Read More

    Press Release | July 16, 2020

    Agent Capital Expands Management Team; Appoints Jacopo Leonardi as Partner

    Read More

    Press Release | July 15, 2020

    Orchard Therapeutics Announces Global License Agreements for Stable Cell Line Technology from GSK

    Read More

    Press Release | July 9, 2020

    ImCheck Therapeutics Appoints Claude Knopf as Chief Business Officer

    Read More

    Press Release | July 9, 2020

    Orchard Therapeutics and MolMed Announce Extension of Gene Therapy Manufacturing Collaboration

    Read More

    Press Release | July 8, 2020

    Precision BioSciences Announces Dosing of First Patient in Phase 1/2a Clinical Trial of PBCAR269A for Multiple Myeloma

    Read More

    News | July 6, 2020

    Bristol Myers Pays Dragonfly $55M to Bring NK Cells to Neuro Diseases

    Read More

    Press Release | July 6, 2020

    Precision BioSciences Regains Rights to In Vivo Hepatitis B Virus Program

    Read More

    Press Release | June 26, 2020

    Aptinyx to be Added to Russell 2000® Index

    Read More

    Press Release | June 18, 2020

    Aptinyx Completes Enrollment in Phase 2 Exploratory Study of NYX-783 in Post-Traumatic Stress Disorder

    Read More

    News | June 3, 2020

    Biotech Pliant Therapeutics pulls off $144M IPO to advance fibrosis pipeline

    Read More

    Press Release | May 28, 2020

    Palvella Therapeutics Completes $45 Million Series C Financing

    Read More

    Press Release | May 26, 2020

    Freenome Announces Initiation of the PREEMPT CRC Clinical Trial for the Early Detection and Prevention of Colorectal Cancer Using a Multiomics Blood Test

    Read More

    Press Release | May 19, 2020

    HalioDx to Characterize the Immune Contexture of Patients Enrolled in ImCheck’s EVICTION Phase 1/2 Clinical Trial

    Read More

    Press Release | May 15, 2020

    New Data from Carisma Therapeutics Uncover Potential of Expedited Pathway for Immunotherapy Development Through CAR Monocytes

    Read More

    Press Release | May 15, 2020

    Orchard Therapeutics Presents New Interim Data from OTL-203 Proof-of-concept Study for MPS-I

    Read More

    News | May 12, 2020

    Merck doubles down on Skyhawk’s tech to drug RNA, promising $600M per autoimmune, metabolic target

    Read More

    News | March 31, 2020

    Latest Penn biotech spinout taking on cancer raises $1.6M from investors

    Read More

    Press Release | March 26, 2020

    First Patient Dosed in EVICTION Trial Evaluating ImCheck’s Lead Anti-Cancer Drug, ICT01: A Novel Gamma Delta T Cell-Activating Immunotherapy

    Read More

    News | March 23, 2020

    First-of-its-kind Engineered Macrophage Cell Therapy Platform Shows Ability to Reduce Tumor Burden and Activate Anti-Tumor Immunity, Improving Overall Survival in Pre-Clinical Cancer Models

    Read More

    Press Release | March 23, 2020

    Pliant Therapeutics Initiates First-in-Human Clinical Trial of PLN-1474 for the Potential Treatment of Liver Fibrosis

    Read More

    Press Release | March 17, 2020

    ImCheck Therapeutics Expands Leadership Team with Appointment of Hans Henrik Chrois Christensen as Chief Financial Officer and Chief Operating Officer

    Read More

    Press Release | March 3, 2020

    Pliant Therapeutics Raises $100 Million in Series C Financing to Advance Therapies for Fibrotic Diseases

    Read More

    News | January 23, 2020

    Business Wire Freenome Announces Encouraging Performance Data for Its Multiomics Blood Test to Detect Early-Stage Colorectal Cancer in a Prospective, Multi-Center Clinical Study

    Read More

    Press Release | January 8, 2020

    Entrada Therapeutics Announces ENTR-501 for the Treatment of Mitochondrial Neurogastrointestinal Encephalomyopathy (MNGIE)

    Read More

    Press Release | January 6, 2020

    Carisma Therapeutics Expands Leadership Team

    Read More

    Press Release | December 4, 2019

    ImCheck Raises $53 Million Series B to Advance Clinical Pipeline of Novel Gamma Delta T-Cell-Focused Antibodies for Cancer and Autoimmune Diseases

    Read More

    Press Release | November 8, 2019

    Precision BioSciences Announces the Presentation of Initial Clinical Data Supporting the Safety and Clinical Activity of PBCAR0191, a Novel CD19 Targeted Allogeneic CAR T Therapy Candidate, at the American Society of Hematology Annual Meeting

    Read More

    Press Release | November 6, 2019

    Orchard Therapeutics to Present New Registrational Data of Investigational Gene Therapies at the 61st American Society of Hematology Annual Meeting

    Read More

    Press Release | October 28, 2019

    Aptinyx Announces Results of Phase 2 Fibromyalgia Study of NYX-2925 Have Been Selected for Late-Breaking Presentation at the American College of Rheumatology Annual Meeting

    Read More

    News | October 23, 2019

    Novartis bets $80M on Pliant’s preclinical NASH prospect

    Read More

    News | July 19, 2019

    Pyxis Oncology Raises $22 Million Series A

    Read More

    News | July 16, 2019

    Genentech inks its latest discovery deal — this time turning to RNA upstart Skyhawk

    Read More

    News | July 8, 2019

    Fattening the bankroll, Bill Haney adds cancer R&D powerhouse Merck to Skyhawk’s roster of partners out to drug RNA

    Read More

    News | June 10, 2019

    Aptinyx Reports Top-line Data from Phase 2 in Patients with Fibromyalgia

    Read More

    News | June 3, 2019

    Carisma Therapeutics Names Dr. Robert Petit As Chief Scientific Officer

    Read More

    News | May 27, 2019

    Carisma Therapeutics Featured in Nature Biotechnology’s Top Academic Spin-outs 2018

    Read More

    Press Release | May 14, 2019

    Precision BioSciences Appoints Christopher R. Heery, M.D., as Chief Medical Officer

    Read More

    Press Release | May 6, 2019

    Skyhawk Therapeutics Announces Agreement with Takeda for Neurodegenerative Diseases

    Read More

    News | April 9, 2019

    Pliant Therapeutics Reports Positive Results Of Phase 1 Clinical Study

    Read More

    News | March 1, 2019

    Genome editing company Precision proposes $100M IPO

    Read More

    News | January 16, 2019

    Aptinyx Reports Top-line Results from Phase 2 Clinical Study of NYX-2925 in Painful Diabetic Peripheral Neuropathy

    Read More

    Press Release | January 4, 2019

    Biogen and Skyhawk Therapeutics Announce Agreement to Develop Novel Small Molecule RNA Splicing Modifiers for Neurological Disease Targets

    Read More

    News | January 3, 2019

    Pliant Therapeutics Initiates Phase 1 Clinical Study of PLN-74809

    Read More

    News | December 18, 2018

    Palvella Therapeutics Announces $10 Million in Funding from Ligand Pharmaceuticals to Accelerate PTX-022 through Phase 2/3 Clinical Study in Pachyonychia Congenita

    Read More

    Press Release | December 18, 2018

    Entrada Therapeutics Raises $59 Million Series A to Advance Intracellular Biologics Platform

    Read More

    Press Release | December 13, 2018

    Orchard Therapeutics Announces the Build-out of New Gene Therapy Manufacturing Facility in California

    Read More

    Press Release | December 6, 2018

    Precision BioSciences and Durham STEM Students Lead Launch of First Genome Editing Experiment Into Space

    Read More

    News | November 27, 2018

    Precision BioSciences Receives FDA Authorization to Initiate Clinical Study of Gene Edited Cancer Immunotherapy

    Read More

    News | November 20, 2018

    Pliant Therapeutics Receives FDA Orphan Drug Designation for Lead Program PLN-74809 in Primary Sclerosing Cholangitis

    Read More

    News | November 5, 2018

    Orchard Therapeutics Announces Closing of $225 Million Initial Public Offering

    Read More

    Press Release | July 16, 2018

    Pliant Therapeutics Raises $62 Million in Series B Financing

    Read More

    Press Release | July 16, 2018

    Verge Genomics Announces $32 Million Series A

    Read More

    News | June 27, 2018

    Carisma Nabs $53 Million Series A for Cellular Cancer Therapy

    Read More

    Press Release | June 26, 2018

    Skyhawk Therapeutics Announces $40 Million Equity Investment Round

    Read More

    News | June 26, 2018

    Kauffman Fellows Celebrates Its Most Diverse Group of Talented Leaders With Class 23

    Read More

    News | June 26, 2018

    Genome Editing Startup Precision BioSciences Scores $110 Million Series B

    Read More

    Press Release | June 26, 2018

    Precision BioSciences Raises $110M

    Read More

    News | June 26, 2018

    Skyhawk Therapeutics Gains $100 Million Through Venture Round, Collaboration

    Read More

    News | June 26, 2018

    CAR Macrophage Tumor Tech Created by UPenn Star Scientists Gets $53M

    Read More

    Press Release | June 20, 2018

    Aptinyx Announces Pricing of Initial Public Offering

    Read More

    News | April 12, 2018

    UK Gene Therapy Firm Orchard Plans Stock Offer After GSK Deal

    Read More

    Press Release | December 20, 2017

    Orchard Therapeutics Announces $110M Series B Financing

    Read More

    Press Release | December 18, 2017

    Aptinyx Raises $70 Million in Series B Financing

    Read More